Literature DB >> 22546123

Lymph node ratio is a significant predictor of disease-specific mortality in patients undergoing esophagectomy for cancer.

Matthew Fox1, Russell Farmer, Charles R Scoggins, Kelly M McMasters, Robert C G Martin.   

Abstract

The seventh edition of the American Joint Committee on Cancer esophageal cancer staging system classifies nodal status by the number of malignant nodes (LNMs) found. This may be confounded by variations in lymphadenectomy and specimen review. The ratio of lymph nodes containing metastases to the total nodes excised (LNR) has been suggested as an alternative. We seek to validate the use of LNR for staging and determine the effect of the total lymph node yield (LNY) on its accuracy. A review of our prospective esophageal database identified 94 patients who underwent esophagectomy for cancer at out institution from 1992 until 2010. Univariate and multivariate analyses were performed. The mean age of our patients was 59.4 years. Transthoracic esophagectomy was performed in all but three instances. The majority of tumors were adenocarcinoma, 76 per cent. Overall survival at 2 and 5 years was 52 and 29 per cent, respectively. LNY correlated with LNM (r = 0.302, P = 0.001) but not LNR (r = 0.012, P = 0.912). Using Kaplan-Meier analysis, LNR had no effect on disease-specific (DS) survival (P = 0.803). However, a Cox proportional hazards regression model showed LNR to be a significant predictor of DS mortality (hazard ratio, 9.47; P = 0.049). The lack of correlation between LNR and LNY suggests that LNR may be a more robust staging method when LNY is low. Furthermore, LNR was found to be a significant predictor of DS mortality when controlling for other factors influencing survival. However, neither a staging system based on LNR nor its efficacy compared with the current system could be determined from these data.

Entities:  

Mesh:

Year:  2012        PMID: 22546123

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  6 in total

1.  Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.

Authors:  Danica N Giugliano; Adam C Berger; Michael J Pucci; Ernest L Rosato; Nathaniel R Evans; Hanna Meidl; Casey Lamb; Daniel Levine; Francesco Palazzo
Journal:  J Gastrointest Surg       Date:  2017-06-29       Impact factor: 3.452

2.  Lymph node dissection in esophageal carcinoma: Minimally invasive esophagectomy vs open surgery.

Authors:  Bo Ye; Chen-Xi Zhong; Yu Yang; Wen-Tao Fang; Teng Mao; Chun-Yu Ji; Zhi-Gang Li
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

3.  Lymph node ratio-based staging system for esophageal squamous cell carcinoma.

Authors:  Shao-Bin Chen; Hong-Rui Weng; Geng Wang; Xiao-Fang Zou; Di-Tian Liu; Yu-Ping Chen; Hao Zhang
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 4.  Lymph node dissection for esophageal cancer.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-03-26

5.  Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Nan Zhang; Junping Shi; Xiaoliang Shi; Wenting Chen; Junfeng Liu
Journal:  Onco Targets Ther       Date:  2020-12-14       Impact factor: 4.147

6.  Optimal Range of Lymphadenectomy in Pathological Stage T1 and T2 Esophageal Squamous Cell Carcinoma.

Authors:  Hansheng Wu; Weitao Zhuang; Shujie Huang; Xueting Guan; Yuju Zheng; Zefeng Xie; Gang Chen; Jiming Tang; Haiyu Zhou; Liang Xie; Xiaosong Ben; Zihao Zhou; Zijun Li; Rixin Chen; Guibin Qiao
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.